Laboratorios Farmaceuticos ROVI SA (ROVI.MC) stock: key figures, P/E, revenue and dividend
Health Care · Spain · ISIN ES0157261019
Laboratorios Farmaceuticos ROVI SA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 763.00 m EUR | 743.00 m EUR |
| Gross profit | 478.00 m EUR | 451.00 m EUR |
| Operating income | 178.71 m EUR | 173.14 m EUR |
| EBIT | 179.00 m EUR | 174.00 m EUR |
| Net income | 136.00 m EUR | 140.00 m EUR |
| Diluted EPS – continuing operations | 2.68 EUR | 2.75 EUR |
Full history since 2003, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Laboratorios Farmaceuticos ROVI SA
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, sterile filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Further, it offers low-molecular-weight heparin, Okedi, and Rolcya; and develops Letrozole SIE and Risperidone QUAR. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain. Laboratorios Farmaceúticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.
More stocks
- Worley Ltd (WOR.AX)
- EquipmentShare.com Inc (EQPT)
- SMG Swiss Marketplace Group Holding AG (SMG.SW)
- Greatland Gold PLC (GGP.L)
- Ningbo Shanshan Co Ltd (600884.SS)
- Guangzhou Haige Communications Group Incorporated Co (002465.SZ)
- PAR PACIFIC HOLDINGS, INC. (PARR)
- Peyto Exploration&Development Corp (PEY.TO)
- China Coal Xinji Energy Co Ltd (601918.SS)
- Apeloa Pharmaceutical Co Ltd (000739.SZ)
- Organon & Co. (OGN)
- Guotai Junan International Holdings Ltd (1788.HK)
Not investment advice. All data without warranty, price as of 28.10.2026. Details in the risk notice.